Feb 12, 2026 04:06PM CVRx, Inc. (CVRX) Misses Q4 EPS by 2c

Jan 22, 2026 04:05PM CVRX begins heart failure trial for expanded patient population

Jan 12, 2026 08:06AM CVRx reports preliminary Q4 revenue of $15.9-16.1 million, issues 2026 guidance

Jan 6, 2026 08:32AM CVRx receives Category I CPT codes for Barostim heart failure therapy

Nov 25, 2025 06:43AM Canaccord Genuity Reiterates Buy Rating on CVRx Inc (CVRX)

Nov 10, 2025 09:17AM CVRx Inc (CVRX) PT Raised to $13 at Cantor Fitzgerald

Nov 6, 2025 08:58AM CVRx (CVRX) files $150M mixed shelf

Nov 6, 2025 04:56AM CVRx Inc (CVRX) PT Raised to $11 at Canaccord Genuity

Nov 5, 2025 04:39PM CVRx, Inc. (CVRX) Tops Q3 EPS by 1c ; Offers Guidance

Aug 11, 2025 07:06AM Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Aug 5, 2025 06:24AM CVRx Inc (CVRX) PT Lowered to $9 at Canaccord Genuity

Aug 4, 2025 04:11PM CVRx, Inc. (CVRX) Misses Q2 EPS by 5c ; Offers Guidance

Jul 16, 2025 07:36AM CMS proposes to maintain outpatient payment for CVRx Barostim procedure

May 9, 2025 04:28AM JPMorgan Downgrades CVRx Inc (CVRX) to Underweight

May 8, 2025 04:27PM CVRx, Inc. (CVRX) Tops Q1 EPS by 1c, provides guidance

Apr 14, 2025 07:04AM Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Apr 8, 2025 08:50AM Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Apr 8, 2025 06:37AM CVRx Inc (CVRX) PT Lowered to $18 at Canaccord Genuity

Mar 18, 2025 06:39AM Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Mar 17, 2025 07:38AM Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer

Feb 13, 2025 09:27AM Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Feb 12, 2025 02:48PM CVRx (CVRX) announces evidence of reduction of hospital visits after Barostim implant

Feb 5, 2025 10:00AM CVRx Inc (CVRX) PT Lowered to $20 at Cantor Fitzgerald

Feb 5, 2025 06:25AM CVRx Inc (CVRX) PT Raised to $23 at Canaccord Genuity

Feb 4, 2025 07:17PM CVRx, Inc. (CVRX) Misses Q4 EPS by 5c

Jan 17, 2025 09:00AM CVRx Inc (CVRX) PT Raised to $22 at Craig-Hallum

Jan 13, 2025 08:14AM CVRx (CVRX) Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

Nov 4, 2024 08:03AM CVRx (CVRX) Announces Positive Outpatient Payment for Barostim Procedure in 2025

Oct 30, 2024 07:55AM CVRx Inc (CVRX) PT Raised to $16 at Piper Sandler

Oct 30, 2024 06:52AM CVRx Inc (CVRX) PT Raised to $17 at Canaccord Genuity

Oct 29, 2024 04:09PM CVRx, Inc. (CVRX) Misses Q3 EPS by 10c ; Offers Guidance

Oct 23, 2024 06:19AM Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Oct 21, 2024 06:25AM Canaccord Genuity Reiterates Buy Rating on CVRx Inc (CVRX)

Oct 18, 2024 02:13PM CVRx (CVRX) announces new CPT Category I codes for Barostim

Sep 10, 2024 06:02AM Cantor Fitzgerald Starts CVRx Inc (CVRX) at Overweight

Sep 3, 2024 08:31AM CVRx (CVRX) Appoints Kevin Ballinger and Mitch Hill to its Board

Aug 2, 2024 08:02AM CVRx (CVRX) Announces Increased Inpatient Payment for Barostim Procedure

Jul 30, 2024 07:24AM CVRx Inc (CVRX) PT Lowered to $13 at Piper Sandler

Jul 30, 2024 06:28AM CVRx Inc (CVRX) PT Raised to $15 at Canaccord Genuity

Jul 29, 2024 04:10PM CVRx, Inc. (CVRX) Misses Q2 EPS by 10c, provides guidance

Jul 11, 2024 08:48AM CVRx Inc (CVRX) PT Lowered to $12 at Lake Street Capital Markets

Jul 10, 2024 12:45PM CVRx (CVRX) sees pressure mid-day; down 12%

Jun 25, 2024 06:50AM CVRx (CVRX) Appoints Robert Allen John as Chief Revenue Officer